Solu-cortef and Urination - excessive volume - a phase IV clinical study of FDA data

Summary:

Urination - excessive volume is reported only by a few people who take Solu-Cortef.

The phase IV clinical study analyzes which people take Solu-cortef and have Urination - excessive volume. It is created by eHealthMe based on reports of 6,371 people who have side effects while taking Solu-cortef from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

6,371 people reported to have side effects when taking Solu-cortef.
Among them, 4 people (0.06%) have Urination - excessive volume.

What is Solu-cortef?

Solu-cortef has active ingredients of hydrocortisone sodium succinate. eHealthMe is studying from 6,388 Solu-cortef users for its effectiveness, alternative drugs and more.

What is Urination - excessive volume?

Urination - excessive volume is found to be associated with 2,002 drugs and 1,237 conditions by eHealthMe.

Number of Solu-cortef and Urination - excessive volume reports submitted per year:

Could Solu-cortef cause Urination - excessive volume?

Time on Solu-cortef when people have Urination - excessive volume *:

Gender of people who have Urination - excessive volume when taking Solu-cortef *:

female: 50 %
male: 50 %

Age of people who have Urination - excessive volume when taking Solu-cortef *:

Common drugs people take besides Solu-cortef *:

Common side effects people have besides Urination - excessive volume *:

Breathing Difficulty: 3 people, 75.00%
Abdominal Pain: 2 people, 50.00%
Thirst - Excessive: 2 people, 50.00%
Fatigue (feeling of tiredness): 2 people, 50.00%
Heart Rate Decreased: 1 person, 25.00%
Dizziness: 1 person, 25.00%
Hepatic Failure (liver failure): 1 person, 25.00%
Cardiac Failure Congestive: 1 person, 25.00%
Cardio-Respiratory Arrest (sudden dysfunction of heart and lungs): 1 person, 25.00%
Chest Pain: 1 person, 25.00%

Common conditions people have *:

Type 2 Diabetes: 1 person, 25.00%
Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 1 person, 25.00%
High Blood Pressure: 1 person, 25.00%
Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 1 person, 25.00%
Chest Pain: 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Solu-cortef and have Urination - excessive volume?

Check whether Urination - excessive volume is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Urination - excessive volume and when was it recovered:

Urination - excessive volume in Solu-cortef

Expand to all the drugs that have ingredients of hydrocortisone sodium succinate:

Urination - excessive volume and drugs with ingredients of hydrocortisone sodium succinate

Alternative drugs to, pros and cons of Solu-cortef:

Solu-cortef (6,388 reports)

Common Solu-cortef side effects:

Fever: 599 reports
Breathing difficulty: 527 reports
Rashes (redness): 469 reports
High blood pressure: 467 reports
Pneumonia: 457 reports
Diarrhea: 456 reports
Hypotension (abnormally low blood pressure): 450 reports

Browse all side effects of Solu-cortef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Urination - excessive volume treatments and more:

Urination - excessive volume (13,876 reports)

COVID vaccines that are related to Urination - excessive volume:

Common drugs associated with Urination - excessive volume:

How the study uses the data?

The study uses data from the FDA. It is based on hydrocortisone sodium succinate (the active ingredients of Solu-cortef) and Solu-cortef (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.